Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883995874> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2883995874 endingPage "S586" @default.
- W2883995874 startingPage "S586" @default.
- W2883995874 abstract "Introduction The use of everolimus (EVE) with tacrolimus (TAC) minimization in renal transplantation is safe and effective in preventing rejection. Postransplant detection of donor specific antibodies (DSA) has been associated with an increased risk of developing rejection and leads to worse graft survival. The aim of our study was to describe the effect of the conversion from mycophenolate mofetil (MMF) with standard exposure TAC to EVE with TAC minimization in stable kidney transplanted recipients, on DSA development. Methods We studied 229 kidney transplants performed consecutively from 07/01/2011 to 12/31/2016. 57 (24,89%) kidney recipients converted from MMF to EVE with TAC minimization was performed. The recipients had stable renal function and no proteinuria. DSA were assessed before transplantation, quarterly during the first year after transplantation, before conversion and at the end of the study. Results Of the 57 patients, 64.9% were male. The mean age was 57.19 ± 15.52 years. The median time from transplant to conversion was 6 months (IQR 2.25-13). The conversion was due to: viral infection 25 (44%), neoplasia 11 (19.3%), nephrotoxicity induced by calcineurin inhibitors 2 (3.5%), indication of the clinician 15 (26.3%) and diarrhea 4 (7%). 7,7% of patients had DSA and 3,5% MICA antibodies before transplantation. We observed a decrease in DSA and MICA antibodies from 6 patients (11.8%) and 2 (3.9%) before conversion to 3 patients (6%) and 0 at the end of the study, respectively. No patient presented acute rejection after conversion. Renal function remained stable, with increased proteinuria at the end of the study. Conclusions In our experience, conversion to EVE allows TAC minimization without increasing DSA production." @default.
- W2883995874 created "2018-08-03" @default.
- W2883995874 creator A5006339739 @default.
- W2883995874 creator A5010790189 @default.
- W2883995874 creator A5019423793 @default.
- W2883995874 creator A5034584618 @default.
- W2883995874 creator A5054471387 @default.
- W2883995874 creator A5076773036 @default.
- W2883995874 creator A5077747703 @default.
- W2883995874 date "2018-07-01" @default.
- W2883995874 modified "2023-10-14" @default.
- W2883995874 title "Donor Specific Antibodies after Conversion from Mycophenolate Mofetil with Standard Exposure Tacrolimus to Everolimus with Tacrolimus Minimization in Stable Kidney Transplanted Recipients" @default.
- W2883995874 doi "https://doi.org/10.1097/01.tp.0000543467.42057.83" @default.
- W2883995874 hasPublicationYear "2018" @default.
- W2883995874 type Work @default.
- W2883995874 sameAs 2883995874 @default.
- W2883995874 citedByCount "1" @default.
- W2883995874 countsByYear W28839958742021 @default.
- W2883995874 crossrefType "journal-article" @default.
- W2883995874 hasAuthorship W2883995874A5006339739 @default.
- W2883995874 hasAuthorship W2883995874A5010790189 @default.
- W2883995874 hasAuthorship W2883995874A5019423793 @default.
- W2883995874 hasAuthorship W2883995874A5034584618 @default.
- W2883995874 hasAuthorship W2883995874A5054471387 @default.
- W2883995874 hasAuthorship W2883995874A5076773036 @default.
- W2883995874 hasAuthorship W2883995874A5077747703 @default.
- W2883995874 hasConcept C126189478 @default.
- W2883995874 hasConcept C126322002 @default.
- W2883995874 hasConcept C126894567 @default.
- W2883995874 hasConcept C128057223 @default.
- W2883995874 hasConcept C159641895 @default.
- W2883995874 hasConcept C2779699572 @default.
- W2883995874 hasConcept C2780091579 @default.
- W2883995874 hasConcept C2780303639 @default.
- W2883995874 hasConcept C2909675724 @default.
- W2883995874 hasConcept C2911091166 @default.
- W2883995874 hasConcept C71924100 @default.
- W2883995874 hasConcept C90924648 @default.
- W2883995874 hasConceptScore W2883995874C126189478 @default.
- W2883995874 hasConceptScore W2883995874C126322002 @default.
- W2883995874 hasConceptScore W2883995874C126894567 @default.
- W2883995874 hasConceptScore W2883995874C128057223 @default.
- W2883995874 hasConceptScore W2883995874C159641895 @default.
- W2883995874 hasConceptScore W2883995874C2779699572 @default.
- W2883995874 hasConceptScore W2883995874C2780091579 @default.
- W2883995874 hasConceptScore W2883995874C2780303639 @default.
- W2883995874 hasConceptScore W2883995874C2909675724 @default.
- W2883995874 hasConceptScore W2883995874C2911091166 @default.
- W2883995874 hasConceptScore W2883995874C71924100 @default.
- W2883995874 hasConceptScore W2883995874C90924648 @default.
- W2883995874 hasIssue "Supplement 7" @default.
- W2883995874 hasLocation W28839958741 @default.
- W2883995874 hasOpenAccess W2883995874 @default.
- W2883995874 hasPrimaryLocation W28839958741 @default.
- W2883995874 hasRelatedWork W1978939233 @default.
- W2883995874 hasRelatedWork W1990739654 @default.
- W2883995874 hasRelatedWork W1997245814 @default.
- W2883995874 hasRelatedWork W2119072362 @default.
- W2883995874 hasRelatedWork W2131345312 @default.
- W2883995874 hasRelatedWork W2400889191 @default.
- W2883995874 hasRelatedWork W2512460450 @default.
- W2883995874 hasRelatedWork W2792710416 @default.
- W2883995874 hasRelatedWork W2884207731 @default.
- W2883995874 hasRelatedWork W4240284178 @default.
- W2883995874 hasVolume "102" @default.
- W2883995874 isParatext "false" @default.
- W2883995874 isRetracted "false" @default.
- W2883995874 magId "2883995874" @default.
- W2883995874 workType "article" @default.